Vertex Pharmaceuticals
VERTEX PHARMACEUTICALS INC / MA (Form: 8-K, Received: 06/04/2015 11:45:12)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2015

VERTEX PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)



MASSACHUSETTS
(State or other jurisdiction of incorporation)
000-19319
(Commission File Number)
04-3039129
(IRS Employer Identification No.)


50 Northern Avenue
Boston, Massachusetts 02210
(Address of principal executive offices) (Zip Code)

(617) 341-6100
(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))







Item 1.01. Entry into a Material Definitive Agreement.
On June 4, 2015, at our 2015 annual meeting of shareholders, our shareholders approved an amendment and restatement of our 2013 Stock and Option Plan that, among other things, increases the number of shares of common stock authorized for issuance under this plan by 7,800,000 shares.

Item 5.07. Submission of Matters to a Vote of Security Holders.
Our annual meeting of shareholders was held on June 4, 2015. Our shareholders elected Sangeeta N. Bhatia, Jeffrey M. Leiden and Bruce I. Sachs to serve on our board of directors until the annual meeting of shareholders to be held in 2018. The tabulation of votes with respect to the election of such directors was as follows:
 
 
For
Withheld
Non-Votes
 
 
 
 
 
Sangeeta N. Bhatia
 
215,763,981

893,591

6,077,182

 
 
 
 
 
Jeffrey M. Leiden
 
210,839,916

5,817,656

6,077,182

 
 
 
 
 
Bruce I. Sachs
 
189,834,052

26,823,520

6,077,182

In addition, our shareholders (i) approved an amendment to our Restated Articles of Organization increasing the number of authorized shares of common stock from 300,000,000 to 500,000,000, (ii) approved an amendment and restatement of our 2013 Stock and Option Plan, (iii) ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2015, (iv) did not approve, on an advisory basis, the compensation program for our named executive officers, (v) approved a shareholder proposal regarding a proxy access by-law and (vi) did not approve a shareholder proposal requesting a report on specialty drug prices. The tabulation of votes with respect to these proposals was as follows:
 
 
For
Against
Abstain
Non-Votes
 
 
 
 
 
 
Amendment to our Restated Articles of Organization
190,445,332

32,052,363

237,059


 
 
 
 
 
Amendment and Restatement of our 2013 Stock and Option Plan
147,055,662

69,353,084

248,826

6,077,182

 
 
 
 
 
Ratification of our Independent Registered Public Accounting Firm
219,360,379

3,144,600

229,775


 
 
 
 
 
Advisory Vote on Executive Compensation
97,683,568

118,709,642

264,362

6,077,182

 
 
 
 
 
Shareholder Proposal on Proxy-Access Bylaw
126,418,279

89,918,865

320,428

6,077,182

 
 
 
 
 
Shareholder Proposal Requesting Report on Specialty Drug Prices
6,283,460

179,710,139

30,663,973

6,077,182

Our board of directors plans to carefully consider the outcome of the advisory vote on the compensation program for our named executive officers and our discussions with and feedback from shareholders in making future decisions regarding our overall executive compensation program and practices.





SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
VERTEX PHARMACEUTICALS INCORPORATED
 
(Registrant)
 
 
Date:  June 4, 2015
/s/ Michael J. LaCascia
 
Michael J. LaCascia
Vice President and Interim General Counsel